Company Profile

ProtATonce is a hi-tech biotechnology company offering novel experimental and computational services in multiplexed assays for Pharmaceutical, Cosmetic, Nutraceutical, Diagnostics, and Life Science companies.

ProtATonce provides a wide range of modular services around Luminex xMAP technology starting from cell culture and compound treatment to assay development, High Throughput Screening (HTS), data acquisition, and advanced data analysis. Early drug discovery applications include Drug Mode of Action, Target Identification and Pathway construction.

Founded in 2012 and run by people from MIT and Harvard, ProtATonce has 99% export activities and in less than two years of operation has achieved three major milestones: a) developed state-of-the art facilities, b) broke even from $1M start up cost, and c) built strong partnerships with the industrial sector (Philip Morris International, IBM, Roche) and leading academic institutes (European Bioinformatics Institute (EBI),  Karolinska Institute, Charité Berlin, University of Zurich, University of Oslo, Fleming Research Center).

ProtATonce played an instrumental role in the design and development of the Species Translation Challenge for the SBV IMPROVER project ( The SBV project, a collaborative effort involving scientists from IBM Research and Philip Morris International, challenges the scientific community to give reliable answers on major industrial problems in biological research. In the SBV Species Translation Challenge scientists from all over the world were asked to develop methods to predict the effects of chemicals in human models given their response in rodent models. Due to the involvement of ProtATonce, the SBV Symposium 2013 took place in Athens where many scientists came from abroad came to Greece to present the results of this challenge.

Target Partners & Collaborations

Protatonce is an early stage drug discovery CRO seeking collaborations/ partnerships with pharmaceutical and life science companies who need to enhance their drug discovery pipeline on the preclinical phase.

ProtATonce is the first company that makes the Multiplex Technology affordable for High Throughput Screening due to its proprietary high quality and cost effective custom assay development. Combined with the strong computational expertise on Systems Pharmacology, ProtATonce can help partners to accelerate their drug discovery pipeline with in-silico predictions validated with in-vitro experiments.

Technologies / Services offered or sought

ProtATonce is an early stage drug discovery CRO that offers multiplex services in drug discovery. Protatonce is offering A-to-Z multiplex services in pharma that range from cell culture, drug library screening, sample preparation, multiplex data acquisition, and advanced computational tools for identification of drug mode of action, lead optimization, target identification, prediction of efficacy etc. The core of the business is the multiplex high throughput screening services with high quality custom assays.

In more details the services that Protatonce is offering are the following:


ProtATonce offers a large range of reliable xMAP measurements using custom made and commercially available assays with Luminex 200 or FlexMap 3D.

  • Select Analytes-> Ship sample-> Get results



  • Screening of compound libraries at a fraction of time
  • Priced significantly lower than commercial assays
  • 800+ assays to choose from
  • Phopshoproteomic & proteomic screening


  • State-of-the-art wet lab and tissue culture for cellular and molecular biology techniques for screening and validation experiments
  • Competitive pricing
  • Knowledgeable experienced personnel


  • High Quality Multiplex Assays at a fraction of time
  • Antibody pairing using advanced optimization algorithms
  • Proprietary technology that quickly rejects promiscuous antibodies


  • Advanced data analysis of your xMAP data
  • Integration with computational tools for drug  discovery


  • Construct a reference signaling network based on publically available repositories and previous experimental data sets.
  • Conduct a phospho-proteomic and proteomic screen in the presence and absence of the drug of interest.
  • Use numerical optimization to fit experimental data into the reference signaling network.
  • Quantify drug effects by identifying drug-induced alterations in the signaling network.


  • dentify targets with optimal clinical efficacy
  • Integrate clinical outcomes with phosphoprotein data sets to identify targets with optimal efficacy in silico
  • Verify your in silico results based on phosphoproteomic experiments


  • Construct signaling pathways based on phosphoproteomic data and advanced computational tools
  • Identify differences between normal and disease pathways
  • Get your leads for the drug discovery portofolio
Postal Address
TE.PA "Lefkippos" – Demokritos,
Patriarchou Grigoriou & Neapoleos
15343 Ag. Paraskevi